-
1
-
-
79952318986
-
Clinical concepts and commentary
-
Weiskopf RB. Clinical concepts and commentary. Anesthesiology 2000;93: 1138-1143.
-
(2000)
Anesthesiology
, vol.93
, pp. 1138-1143
-
-
Weiskopf, R.B.1
-
2
-
-
0027166359
-
Preemptive analgesia: Treating postoperative pain by preventing the establishment of central sensitization
-
Woolf CJ, Chong MS. Preemptive analgesia: treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77:362-379.
-
(1993)
Anesth Analg
, vol.77
, pp. 362-379
-
-
Woolf, C.J.1
Chong, M.S.2
-
3
-
-
33644787497
-
The challenge of preemptive analgesia
-
Aida S. The challenge of preemptive analgesia. Pain 2005;13:1-4.
-
(2005)
Pain
, vol.13
, pp. 1-4
-
-
Aida, S.1
-
4
-
-
34249789001
-
Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo
-
Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol 2007;85:209-214.
-
(2007)
Can J Physiol Pharmacol
, vol.85
, pp. 209-214
-
-
Hou, Y.P.1
Zhang, Y.P.2
Song, Y.F.3
Zhu, C.M.4
Wang, Y.C.5
Xie, G.L.6
-
5
-
-
34548567008
-
Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their antinociceptive potential
-
Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their antinociceptive potential. J Cell Sci 2007;120:2864-2874.
-
(2007)
J Cell Sci
, vol.120
, pp. 2864-2874
-
-
Meng, J.1
Wang, J.2
Lawrence, G.3
Dolly, J.O.4
-
6
-
-
44049104774
-
Glutamate uptake and release by astrocytes are enhanced by Clostridium botulinum C3 protein
-
Höltje M, Hofmann F, Lux R, Veh RW, Just I, Ahnert-Hilger G. Glutamate uptake and release by astrocytes are enhanced by Clostridium botulinum C3 protein. J Biol Chem 2008;283:9289-9299.
-
(2008)
J Biol Chem
, vol.283
, pp. 9289-9299
-
-
Höltje, M.1
Hofmann, F.2
Lux, R.3
Veh, R.W.4
Just, I.5
Ahnert-Hilger, G.6
-
7
-
-
34249742661
-
Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin
-
Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007;130:76-83.
-
(2007)
Pain
, vol.130
, pp. 76-83
-
-
Tugnoli, V.1
Capone, J.G.2
Eleopra, R.3
-
8
-
-
0019619833
-
The origin, structure, and pharmacological activity of botulinum toxin
-
Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-188.
-
(1981)
Pharmacol Rev
, vol.33
, pp. 155-188
-
-
Simpson, L.L.1
-
9
-
-
0034926291
-
The vanilloid receptor: A molecular gateway to the pain pathway
-
Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001;24:487-517.
-
(2001)
Annu Rev Neurosci
, vol.24
, pp. 487-517
-
-
Caterina, M.J.1
Julius, D.2
-
10
-
-
0037179755
-
p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia
-
Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68.
-
(2002)
Neuron
, vol.36
, pp. 57-68
-
-
Ji, R.R.1
Samad, T.A.2
Jin, S.X.3
Schmoll, R.4
Woolf, C.J.5
-
11
-
-
0037435881
-
Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons
-
Amaya F, Oh-hashi K, Naruse Y, et al. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res 2003;963:190-196.
-
(2003)
Brain Res
, vol.963
, pp. 190-196
-
-
Amaya, F.1
Oh-hashi, K.2
Naruse, Y.3
-
12
-
-
0031563769
-
Microinjections of muscimol into lateral superior colliculus disrupt orienting and oral movements in the formalin model of pain
-
Wang S, Redgrave P. Microinjections of muscimol into lateral superior colliculus disrupt orienting and oral movements in the formalin model of pain. Neuroscience 1997;81:967-988.
-
(1997)
Neuroscience
, vol.81
, pp. 967-988
-
-
Wang, S.1
Redgrave, P.2
-
13
-
-
9644279795
-
Descending control of persistent pain: Inhibitory or facilitatory?
-
Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Rev 2004;46:295-309.
-
(2004)
Brain Res Rev
, vol.46
, pp. 295-309
-
-
Vanegas, H.1
Schaible, H.G.2
-
14
-
-
2942604988
-
Clinical presentation and management of antibody-induced failure of botulinum toxin therapy
-
Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19(Suppl 8):S92-S100.
-
(2004)
Mov Disord
, vol.19
, Issue.SUPPL 8
-
-
Dressler, D.1
-
15
-
-
33645855860
-
Botulinum neurotoxins and formalin-induced pain: Central vs. peripheral effects in mice
-
Luvisetto S, Marinelli S, Lucchetti F, et al. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res 2006;1082: 124-131.
-
(2006)
Brain Res
, vol.1082
, pp. 124-131
-
-
Luvisetto, S.1
Marinelli, S.2
Lucchetti, F.3
-
16
-
-
26444469528
-
Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
-
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicol 2005;26:785-793.
-
(2005)
NeuroToxicol
, vol.26
, pp. 785-793
-
-
Aoki, K.R.1
-
17
-
-
0346094286
-
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
-
Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133.
-
(2004)
Pain
, vol.107
, pp. 125-133
-
-
Cui, M.1
Khanijou, S.2
Rubino, J.3
Aoki, K.R.4
-
18
-
-
27144451747
-
An open study of botulinum-A toxin treatment of trigeminal neuralgia
-
Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005;65:1306-1308.
-
(2005)
Neurology
, vol.65
, pp. 1306-1308
-
-
Piovesan, E.J.1
Teive, H.G.2
Kowacs, P.A.3
della Coletta, M.V.4
Werneck, L.C.5
Silberstein, S.D.6
-
19
-
-
33749069285
-
A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis
-
BoNTA-024- 026-036 Study Group
-
Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024- 026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7:688-696.
-
(2006)
J Pain
, vol.7
, pp. 688-696
-
-
Elkind, A.H.1
O'Carroll, P.2
Blumenfeld, A.3
DeGryse, R.4
Dimitrova, R.5
-
20
-
-
34249797267
-
A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches
-
European BoNTA Headache Study Group
-
Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27:492-503.
-
(2007)
Cephalalgia
, vol.27
, pp. 492-503
-
-
Relja, M.1
Poole, A.C.2
Schoenen, J.3
Pascual, J.4
Lei, X.5
Thompson, C.6
-
21
-
-
33846136926
-
Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: A five-year long experience
-
Farinelli I, Coloprisco G, De Filippis S, Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-412.
-
(2006)
J Headache Pain
, vol.7
, pp. 407-412
-
-
Farinelli, I.1
Coloprisco, G.2
de Filippis, S.3
Martelletti, P.4
-
22
-
-
34248372532
-
Botulinum toxin type A in chronic migraine
-
Freitag FG. Botulinum toxin type A in chronic migraine. Expert Rev Neurother 2007;7:463-470.
-
(2007)
Expert Rev Neurother
, vol.7
, pp. 463-470
-
-
Freitag, F.G.1
-
23
-
-
54849435847
-
Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain
-
Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64:274-283.
-
(2008)
Ann Neurol
, vol.64
, pp. 274-283
-
-
Ranoux, D.1
Attal, N.2
Morain, F.3
Bouhassira, D.4
-
24
-
-
67549127798
-
Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial
-
Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;72:1473-1478.
-
(2009)
Neurology
, vol.72
, pp. 1473-1478
-
-
Yuan, R.Y.1
Sheu, J.J.2
Yu, J.M.3
|